Shattuck Labs Announces Participation in Upcoming 21st Annual Needham Virtual Healthcare Conference
April 05, 2022 17:00 ET
|
Shattuck Labs, Inc.
AUSTIN, TX and DURHAM, NC, April 05, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins...
Shattuck Labs Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights
March 15, 2022 07:00 ET
|
Shattuck Labs, Inc.
– Presented positive initial dose-escalation clinical data for SL-172154, including high target occupancy, dose-dependent immune activation, and unique safety profile in heavily pretreated cancer...
Shattuck Labs to Present Two Posters at the 2022 American Association for Cancer Research (AACR) Annual Meeting
March 09, 2022 08:21 ET
|
Shattuck Labs, Inc.
AUSTIN, Texas and DURHAM, N.C., March 09, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional...
Shattuck Labs Announces Participation in Upcoming March Conferences
March 02, 2022 08:39 ET
|
Shattuck Labs, Inc.
AUSTIN, TX and DURHAM, NC, March 02, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion...
Shattuck Labs Announces Participation in Upcoming 11th Annual SVB Leerink Global Healthcare Conference
February 09, 2022 17:00 ET
|
Shattuck Labs, Inc.
AUSTIN, TX and DURHAM, NC, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion...
Shattuck Labs Announces Participation in Upcoming January Investor Conferences
January 05, 2022 08:30 ET
|
Shattuck Labs, Inc.
AUSTIN, TX and DURHAM, NC, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as...
Shattuck Labs to Present at TIGIT Therapies Digital Summit 2021
December 02, 2021 07:17 ET
|
Shattuck Labs, Inc.
AUSTIN, TX and DURHAM, NC, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of...
Shattuck Labs Reports Third Quarter 2021 Financial Results and Recent Business Highlights
November 09, 2021 08:00 ET
|
Shattuck Labs, Inc.
– Announced initial Phase 1 dose-escalation data from SL-172154 in ovarian cancer and SL-279252 in solid tumors at the Society for Immunotherapy of Cancer (SITC) annual meeting; both clinical trials...
Shattuck Labs Announces Preliminary Clinical Data from Ongoing Phase 1 Clinical Trials of ARC Fusion Proteins SL-172154 and SL-279252
November 09, 2021 08:00 ET
|
Shattuck Labs, Inc.
– SL-279252 (PD1-Fc-OX40L) demonstrates anti-tumor activity and evidence of dose-dependent immune activation in heavily pretreated, checkpoint experienced patients – – SL-172154 (SIRPα-Fc-CD40L)...
Shattuck Labs to Host Conference Call and Webcast Highlighting Data Presented at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 04, 2021 07:00 ET
|
Shattuck Labs, Inc.
– Event scheduled for Friday, November 12, 2021 at 8:00 a.m. ET – AUSTIN, TX and DURHAM, NC, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage...